Qi Qi1, Chen Chen2, Chang Liu3, Bin Zhang4, Yuchen Ma5, Hua Zhang6, Wuhao Huang7, Changli Wang8. 1. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: qiqi@tmu.edu.cn. 2. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: chen_chen@tmu.edu.cn. 3. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: liuchang0392@tmu.edu.cn. 4. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: binzh1028@163.com. 5. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: myctardis@outlook.com. 6. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: only_zh@tmu.edu.cn. 7. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: huangwuhao@tmu.edu.cn. 8. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300202, China; National Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300202, China; Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin 300202, China. Electronic address: wangchangli@tjmuch.com.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common cancer and has poor prognosis. Long non-coding RNA(LncRNA) plays important roles in the regulation of cell migration in various types of cancer. In this study, we aimed to demonstrate the function of linc8087 in regulating cell migration and invasion in NSCLC cells. METHODS: A lncRNA microarray was used to identify differentially expressed lncRNAs between NSCLC tissues and normal tissues. RT-qPCR was used to confirm the expression of linc8087 in tumor tissues. The association between linc8087 expression and clinicopathological characteristics was analyzed. RNA fluorescence in situ hybridization (FISH) was performed to observe the subcellular localization of linc8087. We investigated the effects of linc8087 expression on cell migration and invasion by wound healing assay, Transwell and invasion assays. The Human Tumor Metastasis RT2 Profiler PCR Array was used to detect and analyze the mRNA levels of 84 genes involved in metastasis. RESULTS: We found that linc8087 expression was obviously decreased in both NSCLC tissues and cell lines compared with paired normal tissues and a normal bronchial epithelium cell line. Low expression of linc8087 was significantly associated with poor survival. In addition, linc8087 was an independent risk factor for survival. Overexpressed linc8087 inhibited cell migration and invasion in A549 and PC9 cell lines. Knockdown of linc8087 promoted cell migration and invasion. The result of RT2 Profiler PCR Array showed that overexpressed linc8087 upregulated the expression of the COL4A2, CST7 and FAT1 genes and led to the downregulation of SERPINE1. CONCLUSIONS: These results indicate that linc8087 plays a key role in the progression of NSCLC, and it may serve as a meaningful prognostic biomarker as well as a latent therapeutic target in NSCLC patients.
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common cancer and has poor prognosis. Long non-coding RNA(LncRNA) plays important roles in the regulation of cell migration in various types of cancer. In this study, we aimed to demonstrate the function of linc8087 in regulating cell migration and invasion in NSCLC cells. METHODS: A lncRNA microarray was used to identify differentially expressed lncRNAs between NSCLC tissues and normal tissues. RT-qPCR was used to confirm the expression of linc8087 in tumor tissues. The association between linc8087 expression and clinicopathological characteristics was analyzed. RNA fluorescence in situ hybridization (FISH) was performed to observe the subcellular localization of linc8087. We investigated the effects of linc8087 expression on cell migration and invasion by wound healing assay, Transwell and invasion assays. The Human Tumor Metastasis RT2 Profiler PCR Array was used to detect and analyze the mRNA levels of 84 genes involved in metastasis. RESULTS: We found that linc8087 expression was obviously decreased in both NSCLC tissues and cell lines compared with paired normal tissues and a normal bronchial epithelium cell line. Low expression of linc8087 was significantly associated with poor survival. In addition, linc8087 was an independent risk factor for survival. Overexpressed linc8087 inhibited cell migration and invasion in A549 and PC9 cell lines. Knockdown of linc8087 promoted cell migration and invasion. The result of RT2 Profiler PCR Array showed that overexpressed linc8087 upregulated the expression of the COL4A2, CST7 and FAT1 genes and led to the downregulation of SERPINE1. CONCLUSIONS: These results indicate that linc8087 plays a key role in the progression of NSCLC, and it may serve as a meaningful prognostic biomarker as well as a latent therapeutic target in NSCLC patients.
Authors: Dan Li; Xiaoli Liu; Ni Jiang; Di Ke; Qiang Guo; Kui Zhai; Hao Han; Xue Xiao; Tengyang Fan Journal: Am J Cancer Res Date: 2022-07-15 Impact factor: 5.942